Sakatani, T.; Kita, Y.; Fujimoto, M.; Sano, T.; Hamada, A.; Nakamura, K.; Takada, H.; Goto, T.; Sawada, A.; Akamatsu, S.;
et al. IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab. Cancers 2022, 14, 263.
https://doi.org/10.3390/cancers14020263
AMA Style
Sakatani T, Kita Y, Fujimoto M, Sano T, Hamada A, Nakamura K, Takada H, Goto T, Sawada A, Akamatsu S,
et al. IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab. Cancers. 2022; 14(2):263.
https://doi.org/10.3390/cancers14020263
Chicago/Turabian Style
Sakatani, Toru, Yuki Kita, Masakazu Fujimoto, Takeshi Sano, Akihiro Hamada, Kenji Nakamura, Hideaki Takada, Takayuki Goto, Atsuro Sawada, Shusuke Akamatsu,
and et al. 2022. "IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab" Cancers 14, no. 2: 263.
https://doi.org/10.3390/cancers14020263
APA Style
Sakatani, T., Kita, Y., Fujimoto, M., Sano, T., Hamada, A., Nakamura, K., Takada, H., Goto, T., Sawada, A., Akamatsu, S., & Kobayashi, T.
(2022). IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab. Cancers, 14(2), 263.
https://doi.org/10.3390/cancers14020263
